4 not yet recruiting, 2 recruiting, 1 completed. 7 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 7 | Not yet recruiting 4, Recruiting 2, Completed 1 |
Follow Donghua Zhang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies - CD7-Positive Hematological Malignancies | Not applicable | Not yet recruiting | Donghua Zhang | 28 | 2026-12-31 | 2026-01-16 |
| A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells - Multiple Myeloma | Not applicable | Not yet recruiting | Donghua Zhang | 28 | 2026-02-15 | 2026-01-29 |
| Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia CLL1 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation - AML, AML (Acute Myeloid Leukemia) | Not applicable | Not yet recruiting | Donghua Zhang | 18 | 2026-01-30 | 2026-01-15 |
| Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies - Relapsed/Refractory B-cell Malignancies | Not applicable | Recruiting | Donghua Zhang | 28 | 2026-01-01 | 2026-01-16 |
| Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma AcNK-Sup003 cell injection - R/R B-NHL, Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL) | Not applicable | Not yet recruiting | Donghua Zhang | 28 | 2025-12-31 | 2026-01-16 |
| Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia allogeneic γδ T cell infusion - High-Risk Acute Myeloid Leukemia | Not applicable | Recruiting | Donghua Zhang | 40 | 2025-07-01 | 2025-11-19 |
| Clinical Study of Selinexor-Based Chemotherapy With Minimal or No Cytotoxic Agents in Treatment-Naïve AML Patients Unsuitable for Intensive Therapy: Focusing on Rapid Reduction of Blast Cells the XAB regimen - AML (Acute Myeloid Leukemia) | Not applicable | Completed | Donghua Zhang | 103 | 2025-01-01 | 2026-07-17 |
Leukemia, Myeloid, Acute (2) · Recurrence (2) · Lymphoma, B-Cell (1) · Multiple Myeloma (1)
Automobiles (1)
China (7)